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Abstract: Gallium-68 (68Ga) has been the subject of increasing interest for its potential in the 
production of radiotracers for diagnosis of diseases. In this work we report the complexation of 
68Ga by the amino acid based tripodal chelate H3Dpaa, and two bifunctional derivatives, 
H3Dpaa.dab and H4Dpaa.ga, under a range of conditions with particular emphasis on the rapid 
complexation of 68Ga at pH 7.4. 100 μM H3Dpaa achieved a radiochemical yield of 95% at pH 7.4 
in 5 minutes at 37 oC. The bifunctional derivatives H4Dpaa.ga and H3Dpaa.dab achieved 94% and 
84% radiochemical yields, respectively, under the same conditions. The resulting Ga(III) 
complexes show thermodynamic stabilities of logKGaDpaa = 18.53, logKGaDpaa.dab = 22.08, 
logKGaDpaa.ga = 18.36. Unfortunately, the resulting radiolabelled species do not present sufficient 
serum stability for in vivo application. Herein we show a flexible synthesis for bifunctional 
chelators based on amino acids that rapidly complex 68Ga under physiological conditions. 
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Introduction 
Positron emission tomography (PET) is a highly sensitive imaging technique that has been widely 
applied in cancer diagnosis through the use of [18F]-fluorodeoxyglucose (FDG).1 However, FDG 
is taken up in all areas of enhanced metabolism.1 More specific, targeted, probes will provide 
improved diagnosis. Whilst incorporation of 18F and 11C into small organic molecules can provide 
a route to targeted probes, this route often requires multistep syntheses with harsh reaction 
conditions that are not compatible with many biomolecules.2, 3 More rapid assessment of new 
targeting motifs may be achievable by exploiting the modular system created by conjugation of 
targeting motifs to bifunctional chelates that complex radiometals such as 68Ga, 64Cu or 89Zr.4, 5 
Of these positron emitting metal isotopes, 68Ga is of particular interest.69 The generator source of 
68Ga allows for local production at the site of use, opening the possibility of individual hospitals 
producing their own radiotracers instead of relying upon centralised production facilities. 
Comparisons can be drawn to the successful 99mTc single photon emission computed tomography 
(SPECT) isotope.10 The 68 minute half-life of 68Ga is amenable to imaging with peptides and other 
molecules with relatively short blood circulation times in vivo.11  
Traditional macrocyclic chelators, including 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-
tetraacetic acid (DOTA), have been successfully applied to 68Ga complexation.1517 Conjugated 
DOTA derivatives have been applied to imaging of neuroendocrine tumours – with [68Ga]-
DOTATATE being recently approved for use by the FDA. However, radiolabeling of DOTA with 
68Ga requires relatively aggressive conditions, a pH of 4 and heating to over 80 oC for efficient 
radiolabeling.15, 18 These conditions limit the range of targeting motifs that can be used with [68Ga]-
DOTA to acid and temperature stable species.  
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A range of chelators have been tested for their 68Ga complexation abilities.4, 12-14 Recent trends in 
chelate design for 68Ga have been to improve the radiolabeling procedure by reducing the 
temperature required for efficient complexation of 68Ga and raising the pH at which this occurs.4, 
12, 19, 20 This is a challenge due to the formation of kinetically inert gallium hydroxide species above 
pH 4.5.6, 10 Radiolabelling at pHs and temperatures close to physiological conditions is necessary 
to maintain the structure of peptides and aptamers. Furthermore, radiolabelling at neutral pH would 
reduce the formulation required after synthesis of the radiotracer, simplifying the tracer production 
procedure. 
The smaller macrocycle, 1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid (NOTA) has been applied 
to 68Ga complexation, and radiolabelling proceeds efficiently at room temperature, although acidic 
conditions are still required.16 Novel, non-macrocyclic chelates THP21 and DATA22 have been 
shown to rapidly complex 68Ga at higher pH values. While the conjugated DATA probe, DATA-
TOC, has only been radiolabelled at pH 4-5,23 THP conjugates , THP-RGD and THP-TATE, were 
radiolabelled at pH 5-6.5.24, 25 Despite this recent progress, rapid radiolabeling with 68Ga at pH 7 
has not yet been widely realised, with few bifunctional chelators capable of achieving rapid 
complexation at neutral pH reported (structures of these bifunctional chelators are shown in figure 
S1).26-28 
Development of alternative chelates that can achieve this may allow for improved design of the 
imaging probe through different pharmacokinetic profiles/biodistributions.29 While THP-TATE 
can be radiolabelled at pH 6.5, its lipophilic nature results in a significantly different 
biodistribution when compared to DOTA-TATE, with longer renal and liver uptake. Balancing 
improved radiolabeling properties with ideal imaging properties requires the development of new 
chelates to optimize both properties.29 
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We report here the application of the chelate N, N-bis[(6-carboxypyridin-2-yl)methyl]glycine 
(H3Dpaa) and two bifunctional derivatives, H3Dpaa.dab and H4Dpaa.ga (Figure 1) to 68Ga 
complexation. H3Dpaa is composed of two picolinic acid arms attached to a central glycine unit to 
produce a tripodal, hexadentate ligand. Picolinic acids have been demonstrated to be highly 
capable 68Ga coordinating arms.30 The aminebis(picolinic acid) motif has been applied to the 
complexation of a variety of metals with a number of different amines being used to form chelates 
with varying properties.3142The incorporation of a glycine residue into the chelate backbone 
provides both a carboxylic acid group that can bind strongly to Ga(III) due to a good hard acid/base 
match, and also a site which can be readily functionalised through application of other amino 
acids.31, 33 H3Dpaa has previously been applied to complexation of lanthanide(III) ions such as 
gadolinium(III) (logKGdDpaa = 10.6)32, 33 and terbium(III) (logKTbDpaa = 10.4).32 H3Dpaa has recently 
been applied to manganese(II) (logKMnDpaa = 13.2),34 lanthanum(III) (logKLaDpaa = 13.6)35 and 
gallium-67 (logKGaDpaa = 18.7)35 complexation showing the versatility of this ligand for metal 
coordination. Herein we show a flexible synthesis for bifunctional chelators that rapidly complex 
68Ga under physiological conditions with a radiochemical yield of up to 95%. Unfortunately, the 
radiolabelled species [68Ga][Ga(Dpaa)], [68Ga][Ga(Dpaa.dab)] and [68Ga][Ga(Dpaa.ga)] show 
poor stability in serum competition studies and are unsuitable for advancing to in vivo studies. 
Results and Discussion 
Synthesis and Characterisation 
In this paper we report the application of N, N-bis[(6- carboxypyridin-2-yl)methyl]glycine 
(H3Dpaa) and two bifunctional derivatives to 68Ga complexation. The ligand H3Dpaa was 
synthesized in two steps as described by Mazzanti et al.32 from ethyl 6-(chloromethyl)picolinate 
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and glycine ethyl ester hydrochloride followed by deprotection under acidic conditions. The 
bifunctional chelates, (S)-6,6'-(((3-amino-1-carboxypropyl)azanediyl)bis(methylene))dipicolinic 
acid (H3Dpaa.dab) and N,N-bis((6-carboxypyridin-2-yl)methyl)-L-glutamic acid (H4Dpaa.ga), 
were synthesised in a similar fashion from the relevant protected amino acid analogues, H-
dab(Boc)-OMe hydrochloride33 and diethyl glutamate hydrochloride as shown in Scheme 1. 
Et4Dpaa.ga was obtained in a 72% yield as a yellow oil. Deprotection of this proligand via acid 
hydrolysis yielded H4Dpaa.ga as an off white solid in an 82% yield. Crystals of H4Dpaa.ga suitable 
for single crystal x-ray diffraction were obtained by precipitation from water. The obtained 
structure† (Figure S22) shows a distinct asymmetry caused by the chirality of the amino acid used. 
The molecule displays a configuration with one picoline ring on top of the other at a separation at 
little over 3 Å. This arrangement facilitates an intramolecular hydrogen bond between the glycine 
carboxylic acid and the pyridine (N2-H2···O6). The second picolinic acid is present with the 
nitrogen protonated and free carboxylate (N1-H1···O7i, where i = x−½, ½−y, z+½). This 
arrangement facilitates an R22(8) embrace to the terminal carboxylic acid group of another 
molecule. In the solid there is an extensive hydrogen bond network. 
Ga(III) complexes were synthesized by addition of GaCl3 to an aqueous solution of the ligand. The 
resulting complexes precipitated out of solution and were collected. 
Evidence for complexation can be seen through the distinct NMR resonances of the two protons 
in the CH2 environment between the picolinate arms and the central amine. While these protons 
are equivalent (δH3Dpaa = 3.92, δH3Dpaa.dab = 4.41, δH4Dpaa.ga = 4.40) on the NMR time scale in the 
free ligands, in the Ga(III) complexes they are inequivalent (δ[Ga(Dpaa)] = 4.62 and 4.48, δ[Ga(Dpaa.dab)] 
= 4.56-4.33 and 4.07, δ[Ga(Dpaa.ga)] = 4.66 and 4.33) and show a strong geminal coupling to one 
another (2JHH = 16-17 Hz).  
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Crystal structure of Ga(III) complexes 
Single crystals of [Ga(Dpaa)] and [Ga(Dpaa.ga)] of a suitable quality for x-ray diffraction were 
obtained from acidic aqueous solutions. In each of the two structures, ‡, § Ga(III) is in a six 
coordinate environment, with five coordination sites occupied by the ligand and the final site by 
water. (Figure 2) The bonds from the Ga(III) atom to nitrogen atoms are rather longer than those 
to the oxygen atoms of the carboxylates (as shown in Table 1). This is a consequence of the strain 
in the ligand and may also reflect the preference of Ga(III) for the hard oxygen donors. The central 
amine atom (N2) in each structure is rather too distant from the Ga(III) to suggest a bond.  
Each structure features a distorted octahedral coordination of the Ga(III) as a consequence of the 
geometry of the ligand. The greatest distortion is obvious in the plane of the picolinic acids (Tables 
1 & 2). In each case the N1-Ga-N3 angle is greater than 133° and consequently the N-Ga-O angles 
are much smaller than the ideal 90° expected for undistorted octahedral geometry.  
[Ga(Dpaa)] is relatively symmetric and there is a pseudo-mirror plane (through O3, N2, and O1w) 
present in the complex. The picolinate arms are close to planar; the angle subtended by the two 
mean planes of the picolinates is 9.53(3)°. In contrast the glutamic acid backbone introduces a 
twist in [Ga(Dpaa.ga)] removing the pseudo-mirror plane and pushing the picolinate rings further 
out of the same plane such that the angle between their mean planes is 15.85(3)°. It is important to 
note that the pendant carboxylate arm of the glutamic acid is not involved in Ga(III) coordination. 
Full crystallographic data can be found in the supplementary information. 
Potentiometry 
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Protonation constants of the studied compounds were determined by potentiometry (Table 3, 
distribution diagrams are shown in Figure S2). The determined protonation constants of H3Dpaa 
are in very good agreement with those previously reported.32, 35 The first protonation constant (pK1 
= 7.38) is assigned to the central amine group. The two remaining constants are ascribed to 
protonation of the picolinate arms. The protonation constant of the pendant acetic acid group could 
not be determined due to its highly acidic nature. 
The additional carboxylate group in H4Dpaa.ga introduces an additional protonation constant in 
the weakly acidic region (pK2 = 4.67). However, it does not alter significantly the protonation 
constants of the ligand core (pK1 = 7.33) or the picolinate arms. The terminal amino group in 
H3Dpaa.dab is protonated above pH 11 (pK1 = 11.35). Presence of the additional protonated amino 
group significantly decreases basicity of the central amino group in the ligand core (pK2 = 5.39). 
Complexation of Ga(III), Cu(II) and Zn(II) ions by the three ligands was studied by potentiometry. 
These metal-ligand systems were chosen due to their importance for the potential application of 
these ligands to nuclear medicine. The results are summarized in Table 4. 
The study of the Ga(III)-Dpaa system was not straightforward due to low solubility of the 
uncharged [Ga(Dpaa)] species. Therefore, UV-VIS titration was performed at significantly lower 
concentration (Figure S4). Nitrogen atoms of the ligands are weakly basic and this leads to 
complexation of metal ions even in strongly acidic solutions. As a consequence, some of the 
complexes were fully formed in the beginning of potentiometric titrations. Thus, Cu(II) and Zn(II) 
systems with H4Dpaa.ga and H3Dpaa.dab were also studied by UV-VIS spectrophotometry at pH 
0–2 (Figure S6 and S8). Spectrophotometry was not employed in Ga(III) systems for these ligands 
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as stability constants could be determined from competition with hydroxide ions in the alkaline 
region (i.e. formation of [Ga(OH)4]−). 
The stability constants of [Ga(L)] species are similar for both H3Dpaa and H4Dpaa.ga. This 
indicates a negligible role of the distant carboxylate in complexation reactions of H4Dpaa.ga in 
agreement with crystallographic data. For [Ga(Dpaa.ga)], the first protonation constant ([M(L)] + 
H ↔ [M(HL)], logK = 4.04, Table S2) is comparable to that of free ligand, further supporting that 
the distant carboxylate group is not coordinated. In both systems, hydroxido species, 
[Ga(HO)(Dpaa)]– and [Ga(HO)(Dpaa.ga)]–, are formed already in acidic region through a formal 
aqua ligand dissociation with corresponding pKa values of 4.41 and 5.27, respectively. 
This points to an unsaturated coordination sphere of the metal ion in these complexes in which 
some of the ligand donor groups remain uncoordinated. The unsaturated coordination sphere is 
corroborated by the crystal structures obtained in which this site is occupied by a bound water 
molecule. Complexes in which the coordination sphere of Ga(III) is not fully satisfied by a chelate 
with six coordinating atoms have been reported previously, with modelling suggesting either water 
of chloride bound in the vacant site.43, 44 Stability constants of the studied Ga(III) complexes are 
significantly higher than those reported for complexes of H3Dpaa with lanthanide(III) ions (logK 
= 10.6 and 10.4 for [Gd(Dpaa)] and [Tb(Dpaa)], respectively).32 This indicates that the ligands 
better suits “hard” and small metal ions such as Ga(III). 
The stability constant for [Ga(Dpaa.dab)] complex (logKGaL = 22.08) is surprisingly much higher 
than those of the other two Ga(III) complexes. This is due to the different structure of the [GaL] 
species. The Ga(III) ion in [Ga(Dpaa)] and [Ga(Dpaa.ga)] complexes is coordinated by the fully 
deprotonated ligand. Ligand H3Dpaa.dab contains the highly basic terminal amino group. 
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Consequently, the proton bound to the coordinated water molecule is more acidic than the proton 
bound to the amino group. The first protonation constant (logKa = 5.40, Table S2) is similar to 
those describing formation of the monohydroxide species in both the Ga(III)-Dpaa and Ga(III)-
Dpaa.ga systems and should be ascribed to the formation of the hydroxide species as well. Thus, 
the [Ga(Dpaa.dab)] complex is zwitterionic, with a hydroxide anion bound to the Ga(III) and with 
a protonated amine group. Dissociation constant of the amino group in the complex cannot be 
determined as it would dissociate at very high pH where the complex is fully decomposed to 
[Ga(OH)4]–. To compare the stability constants, it is more suitable to consider equilibrium between 
Ga(III) ion and monoprotonated ligand molecule (logKGaHL 16.13, Table 4) where influence of the 
above processes is not considered. The value is lower and in line with those for the other systems 
if the presence of a positive charge, due to a protonated amino group in the ligand molecule, is 
taken into account. This is reflected in the pM values which are 8.91, 6.34 and 8.21 (pH =7.4, [Ga] 
= 10–6 M, [L] = 10–5 M) for [Ga(Dpaa)], [Ga(Dpaa.dab)] and [Ga(Dpaa.ga)], respectively. When 
comparing the formation constant of [Ga(Dpaa)] of 18.53 with that of [Ga(DOTA)] and 
[Ga(NOTA)] (logKGaL = 26.05 and 29.60, respectively)45, 46 the thermodynamic stability is lower, 
but still it may be sufficient for the application due to the short half-life of 68Ga.  
The stability constants obtained for [Cu(Dpaa)] and [Zn(Dpaa)] complexes are significantly lower 
than that of the Ga(III) complex (Tables S2 and S3). This may be rationalized due to the low 
flexibility of the ligand preventing the complex from fulfilling the ideal coordination geometry of 
these two ligands and due to the high charge density of Ga(III) compared to Cu(II) and Zn(II). The 
ligands are highly charged with hard oxygen donor atoms and interaction of the ligands with 
Ga(III) is highly electrostatic in its nature and, therefore, thermodynamic stability of the Ga(III) 
complexes is increased compared to Cu(II) and Zn(II) complexes. This preference for Ga(III) 
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complexation is encouraging for biomedical imaging using [68Ga][Ga(Dpaa)] as Cu(II) and Zn(II) 
are two of the most abundant transition metal ions in vivo.47 
Whilst the Cu(II) and Zn(II) complexes of H3Dpaa.dab and H4Dpaa.ga are less thermodynamically 
stable than the Ga(III) complexes, the resulting complexes are more stable than those seen with 
H3Dpaa. This suggests that the additional coordinating arms may be involved in the complexation 
of these two metals. 
Radiolabelling 
The radiochemical yield (RCY) of H3Dpaa complexing 68Ga was found to have a distinct pH 
dependence (Figure 4); in acidic aqueous solution the radiochemical yield achieved by 100 μM 
H3Dpaa was very high up to pH 4, with a radiochemical yield >95% achieved in 15 minutes at 
ambient temperature. Above pH 5 the radiochemical yield at ambient temperature fell to 
approximately 30% after a reaction time of 15 minutes. This is likely due to the formation of 
gallium hydroxide species with slower complexation kinetics above pH 4.6, 13 However, in the 
presence of 0.1 M phosphate buffer the high RCY was maintained up to pH 7.5, with a 92% yield 
being achieved in 15 minutes at ambient temperature. Under these conditions ([L] = 100 μM, pH 
= 7.5, T = 25 oC, I = 0.1 M phosphate buffer, t = 15 minutes), macrocyclic chelators DOTA (0% 
RCY) and NOTA (48% RCY) performed poorly, but acyclic chelates EDTA (95% RCY) and THP 
(95% RCY) performed comparably to H3Dpaa (Table S4). Above pH 8 the RCY of H3Dpaa fell 
even in buffered solutions, likely due to the formation of [Ga(OH)4]- as indicated by the 
potentiometric results (Figure 3). When heated to 37 oC the radiochemical yield achieved at pH 
7.5 by 100 μM H3Dpaa in 15 minutes increased to 95%. 
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This difference between buffered and aqueous solutions may be explained by a weak gallium-
phosphate complex being formed. This may act as a “pre-coordination” complex, preventing the 
rapid formation of gallium hydroxide species that would result in slower complexation due to the 
kinetically inert gallium-hydroxide bonds.19 
The pH of the radiolabelling reaction also has a significant effect on the concentration of ligand 
required for efficient radiolabelling (Figure 5). When radiolabelling at pH 4, efficient 
complexation is achieved at ligand concentrations as low as 500 nM, with radiochemical yields 
>90% achieved in 15 minutes at ambient temperature. However, the radiochemical yield sharply 
decreases below this concentration with no radiolabelling seen when [H3Dpaa] = 100 nM. In 
contrast, at pH 7.4 the radiochemical yield after 15 minutes at ambient temperature is maintained 
above 90% at 50 μM, however drops below 90% at ligand concentrations of 10 μM. 
The ability to rapidly complex 68Ga at neutral pH has the potential to simplify the production of 
68Ga labelled radiopharmaceuticals by reducing the post-reaction conditioning required. To 
develop this further, the complexation of 68Ga by 100 μM H3Dpaa in saline and phosphate buffered 
saline (PBS) was assessed. High radio-chemical yields of 99% and 95% respectively were 
achieved with mild heating (37.7 oC) after 5 minutes. Furthermore, the pH of the PBS solution 
remained at pH 7.4 after complexation, although the pH of the saline solution was lower (pH 5.5) 
after addition of the ligand. 
The bifunctional chelates H3Dpaa.dab and H4Dpaa.ga achieved 99% RCYs after 5 minutes at pH 
4 and ambient temperature, and the RCY remained as high as 84% and 94% respectively at pH 7.4 
in PBS after 5 minutes at 37 oC(Table 5, Figure S9). Specific activities of 20.0 GBq μmol-1 (541 
mCi μmol-1) and 28.9 GBq μmol-1 (781 mCi μmol-1) were achieved with H3Dpaa.dab and 
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H3Dpaa.ga respectively (Figure S12 and S13) after radiolabelling at pH 4 (T = 25 oC, t = 5 minutes, 
I = 0.1 M acetate buffer), however H3Dpaa achieved a specific activity of only 3.9 GBq μmol-1 
(105 mCi μmol-1)(Figure S11). 
The stability of the radiolabelled complexes formed were assessed against biological competitors, 
apo-transferrin and foetal bovine serum (FBS). Some stability to the iron transport protein apo-
transferrin was seen, 92% of 68Ga activity was associated with the [68Ga][Ga(Dpaa)] complex after 
2 hours of incubation (Figure S14). In FBS complete decomplexation of the 68Ga was seen within 
30 minutes for all chelate derivatives (Figure S15). This suggests that having the vacant 
coordination site filled by H2O (Figure 2), allows for 68Ga to be more readily taken up by 
competitor proteins found in the serum and therefore H3Dpaa is not the ideal system for 68Ga 
application in vivo. 
Conclusions 
We describe a ligand system based on amino acids allowing for synthesis of bifunctional chelators. 
This family of ligands are able to complex 68Ga under physiological conditions (5 minutes, pH 7.4 
and T = 37.7 oC) at 100 μM. The H3Dpaa family of ligands are also able to complex 68Ga efficiently 
across a wide pH range. The ligands presented here are more suited to the complexation of small, 
hard cations like Ga(III) than they are to softer Zn(II) and Cu(II) cations, as indicated by their 
higher association constants. Studies with biological competitors, FBS and apo-transferrin suggest 
that these chelates are not suited for in vivo application with 68Ga. However the chelator’s 
preference for Ga(III) and the high radiochemical yield achievable under physiological pH and 
temperature provides the groundwork to support future studies into acyclic chelators for 68Ga. 
Experimental Section 
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NMR spectra were recorded on a JEOL ECP 400 MHz / JEOL Lambda 400 MHz spectrometer 
using the residual protic solvent signal as an internal reference. ESI Mass spectra were recorded 
on Advion MS SOP electrospray ionisation spectrometer. pH measurements were carried out using 
a Jenway model 3520 pH/mV/Temperature meter with a three point calibration. All commercially 
available starting materials were used without further purification. Ethyl 6-
(chloromethyl)picolinate was synthesised from 2,6-dipicolinic acid according to literature 
methods.49, 50 H3Dpaa and H3Dpaa.dab were synthesised according to literature methods.32, 33 
Synthesis of Et4Dpaa.ga 
To a suspension of l-glutamic acid diethyl ester hydrochloride (1.82 g, 7.6 mmol), potassium 
carbonate (4.00 g, 28.9 mmol) and potassium iodide (2.64 g, 15.9 mmol) in anhydrous acetonitrile 
(10 mL) was added ethyl 6-(chloromethyl)picolinate hydrochloride (3.75 g, 15.9 mmol). The 
mixture was heated to 60 oC for 12 hours. The reaction was quenched with water (50 mL) and 
extracted with dichloromethane (3 x 100 mL). The combined organic layers were dried with 
magnesium sulfate and concentrated under reduced pressure. The dark orange oil was purified by 
column chromatography (silica, 50 mm x 150 mm, Hexane/Ethyl Acetate 20-50%) to yield an 
orange oil (2.91 g, 5.5 mmol, 72%) 
1H NMR (400 MHz, CDCl3, 298 K): 7.95 (dd, 2 H, J = 6, 2.5 Hz), 7.76 (m, 4H, py), 4.46 (q, 4 H, 
3JHH = 7.1 Hz), 4.22 (qd, 2 H, 3JHH = 7.1 Hz, J = 1.8 Hz), 4.16 (d, 2 H, 2JHH = 15.5 Hz), 4.10 (d, 2 
H, 2JHH = 15.5 Hz), 4.01 (qt, 2 H, 3JHH = 7.1 Hz, J = 3.7 Hz), 3.45 (dd, 1 H, J = 9.2, 6.1 Hz), 2.50 
(m, 2 H), 2.13 (tq, 1 H, 2JHH = 14.1 Hz, 3JHH = 7.5 Hz), 2.02 (dqt, 1 H, 2JHH = 14 Hz, 3JHH = 7.5 
Hz, J = 1.6 Hz), 1.44 (t, 6 H, 3JHH = 7.1 Hz), 1.33 (t, 3 H, 3JHH = 7.1 Hz), 1.18 (t, 3 H, 3JHH = 7.1 
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Hz) 13C NMR (100 MHz, CDCl3, 298 K): 173.04, 172.36, 165.26, 160.23, 147.76, 137.21, 125.93, 
123.35, 62.33, 61.73, 60.65, 60.25, 57.08, 30.66, 24.79, 14.38, 14.25, 14.08. 
 
Synthesis of H4Dpaa.ga 
To Et4Dpaa.ga (887 mg, 1.72 mmol) was added 6 M HCl (14 mL). The solution was heated to 
reflux for 16 hours and then allowed to cool to room temperature. The solvent was removed to 
yield a yellow oil. Acetone (10 mL) was added to yield an off-white precipitate (617 mg, 1.26 
mmol, 73 %). 
1H NMR (400 MHz, D2O (pD = 7.1), 298 K), δ: 7.72-7.55 (m, 4 H), 7.42-7.32 (m, 2 H), 4.47-4.33 
(m, 4 H), 3.77-3.63 (m, 1 H), 2.43-2.27 (m, 2H), 2.27-2.06 (m, 2 H). 13C NMR (100 MHz, D2O 
(pD = 7.1), 298 K), δ: 181.70, 176.22, 171.57, 153.47, 151.81, 138.88, 126.17, 123.11, 69.52, 
57.14, 34.51, 25.67 MS (ESI), m/z: 418.04 [M+H]+. Elemental Analysis (C/H/N), %: Expected for 
H4Dpaa.ga.2HCl (C19H21Cl2N3O8): 46.55/4.32/8.57 Found: 46.22/4.40/7.99 
H3Dpaa 
Et3Dpaa (38 mg, 0.089 mmol) in 6M HCl (6 mL) was heated to reflux for 16 h. The sample was 
concentrated, ethanol added, and the precipitate collected and washed with diethyl ether to yield a 
white solid (36.5 mg, 0.089 mmol, 100%) 
1H NMR (400 MHz, D2O (pD = 8.8), 298 K), δ: 7.72-7.62 (m, 4 H), 7.38 (br d, 2 H, 3JHH = 7.8 
Hz), 3.92(br s, 4 H), 3.27 (br s, 2 H). 13C NMR (100 MHz, D2O (pD = 8.8), 298 K), δ: 172.96, 
152.71, 138.14, 125.87, 122.35, 60.07, 59.22 MS(ESI), m/z = 346.4 [M+H]+. Elemental Analysis 
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(C/H/N), %: Expected for H3Dpaa.1.3(HCl)0.25(diethyl ether) (C17H19.05Cl1.3N3O6.25): 
49.62/4.67/10.21 Found: 49.63/4.40/9.94 
H3Dpaa.dab 
Et2MeDpaa.dab(Boc) (676.4 mg, 1.21 mmol) was dissolved in 6 M HCl (20 mL) and heated to 
reflux overnight. The solvent was removed under reduced pressure to yield a yellow oil. Addition 
of acetone resulted in precipitation of a solid. Isolation of this precipitate yielded a yellow solid 
(446.3 mg, 0.84 mmol, 70%). 
1H NMR (400 MHz, D2O (pD = 1.6), 298 K), δ: 8.09 (t, 2 H, 3JHH = 7.8 Hz), 7.96 (d, 2 H, 3JHH = 
7.8 Hz), 7.71 (d, 2 H, 3JHH = 7.8 Hz), 4.41 (s, 4 H), 4.00 (t, 1 H, 3JHH = 7.3 Hz), 3.37-3.18 (m, 2 
H), 2.40-2.23 (m, 2 H). 13C NMR (100 MHz, D2O (pD = 1.6), 298 K), δ: 174.50, 164.62, 154.61, 
145.26, 143.74, 128.24, 124.92, 64.99, 55.53, 37.66, 26.10. MS (ESI) m/z: 389.4 [M+H]+. 
Elemental Analysis (C/H/N), %: Expected for H3Dpaa.dab(HCl)3(Acetone)0.55 
(C19.65H28.3Cl3N4O7.55): 43.09/5.21/10.23 Found 42.85/5.15/9.93 
Synthesis of [Ga(Dpaa.ga)] 
To H4Dpaa.ga (25 mg, 0.062 mmol) in a solution of methanol (1 mL) and water (1 mL) was added 
GaCl3 (10.9 mg, 0.062 mmol) in water (1.2 mL). The solution was heated to 70 oC for 16 hours 
and allowed to cool. The precipitate was collected by centrifugation (4000 rpm, 3 minutes) to give 
a white solid (14.6 mg, 0.026 mmol, 42%). 
1H NMR (400 MHz, D2O (pD = 6.0), 298 K) δ: 8.30-8.11 (m, 4 H), 7.81-7.73 (m, 2 H), 4.66 (br 
d, 2 H, 2JHH = 17 Hz), 4.33 (br d, 2 H, 2JHH = 17 Hz), 3.05-2.97 (m, 1 H), 2.44-2.33 (m, 1 H), 2.26-
2.15 (m, 1 H), 2.06-1.88 (m, 2 H). 13C NMR (100 MHz, D2O (pD = 6.0), 298 K) δ: 180.94, 178.13, 
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168.10, 152.32, 151.03, 144.69, 144.45, 142.83, 142.76, 127.57, 126.38, 123.11, 123.06, 62.08, 
58.28, 53.07, 34.80, 22.33. MS (ESI), m/z: 483.94 [69GaM+H]+, 485.97 [71GaM+H]+. Elemental 
Analysis (C/H/N), %: Expected for GaDpaa.ga(COOH).3.5H2O.0.5MeOH (C19.5H25GaN3O12): 
41.59/4.47/7.46 Found: 41.56/4.68/7.42 
Synthesis of [Ga(Dpaa)] 
To H3Dpaa (76 mg, 0.22 mmol) in water (5 mL) was added GaCl3 (38.8 mg, 0.22 mmol) in water 
(3.8 mL). The pH was adjusted to 4.5 with sodium hydroxide. The solution was heated to reflux 
for 3 days. After cooling, the solution was filtered to give a white solid (76 mg, 0.14 mmol, 64%). 
1H NMR (400 MHz, D2O (pD = 8.8), 298 K) δ: 8.21 (t, 2 H, 3JHH = 7.3 Hz), 8.14 (d, 2 H, 3JHH = 
7.3 Hz), 7.75 (d, 2 H, 3JHH = 7.3 Hz), 4.62 (dd, 2 H, 2JHH = 16.0 Hz, 4JHH = 2.75 Hz), 4.48 (br d, 2 
H, 2JHH = 16.0 Hz), 3.39 (d, 2 H, 4JHH = 2.3 Hz). 13C NMR (100 MHz, D2O (pD = 8.8), 298 K) δ: 
176.86, 168.40, 151.26, 144.57, 142.35, 126.76, 122.99, 60.60, 59.89. MS (ESI), m/z: 411.95 
[69GaM+H]+, 413.89 [71GaM+H]+. Elemental Analysis (C/H/N), %: Expected for 
GaDpaa.H2O.3HCl (C16H17Cl3GaN3O7): 35.63/3.18/7.79 Found: 35.85/3.09/7.59 
Synthesis of [Ga(Dpaa.dab)] 
To H3Dpaa.dab (25 mg, 0.064 mmol) in methanol (5 mL) was added GaCl3 (11.3 mg, 0.064 mmol) 
in water (1.2 mL). This solution was heated to 70 oC for 1 hour and allowed to cool. The precipitate 
was collected by centrifugation (4000 rpm, 3 minutes) to give a white solid (17 mg, 0.039 mmol, 
60%) 
1H NMR (400 MHz, D2O (pD = 1.1), 298 K) δ: 8.32-8.24 (m, 2 H), 8.24-8.12 (m, 2 H), 7.88-7.75 
(m, 2 H), 4.56-4.33 (m, 3 H), 4.07 (br d, 1 H, 2JHH = 17.4 Hz), 3.18-3.12 (m, 1 H), 3.11-3.02 (m, 2 
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H), 2.28-2.07 (m, 3 H). 13C NMR (100 MHz, D2O (pD = 1.1), 298 K) δ: 177.21, 167.18, 167.05, 
153.37, 152.71, 145.06, 144.69, 143.97, 128.49, 127.67, 123.77, 123.63, 61.19, 65.00, 51.95, 
38.11, 30.30, 24.07. MS (ESI), m/z: 454.43 [69GaM+H]+, 456.39 [71GaM+H]+. Elemental Analysis 
(C/H/N), %: Expected for GaDpaa.dab(NH2).H2O.0.9HCl (C18H19.9Cl0.9GaN4O7): 
42.73/3.97/11.07 Found: 43.02/3.63/10.87 
Potentiometry 
Potentiometry was carried out according to previously published procedures.51, 52 Protonation and 
stability constants were determined in 0.1 M (NMe4)Cl at 25.0 °C with pKw = 13.81. Protonation 
constants ([L] = 0.004 M) were determined from data obtained in pH range 1.6–12.1 (~40 points 
per titration and three parallel titrations) with electrode calibrated by acid-base titration in extended 
pH ranges (1.7–12.2 for each titration set). Complex stability constants ([L] = [M] = 0.004 M) 
were determined from data obtained in pH range 1.5–12.1, 50 data points per titration, three 
parallel titrations). 
UV-VIS spectra were recorded on spectrophotometer Specord 50 Plus (Analytik Jena AG). 
Temperature was maintained by Peltier block. UV-VIS titration of the Ga(III)-H3Dpaa system ([L] 
= [M] = 0.0001 M) was performed at pH range 2.4–6.9 in 0.1 M (NMe4)Cl, pH was adjusted with 
~0.2 M (NMe4)OH using a glass electrode. UV-VIS titrations of the Cu(II) and Zn(II) systems 
with H4Dpaa.ga and H3Dpaa.dab ([L] = [M] = 0.00001 M) were performed at pH range 0.0–2.0 
without ionic strength control, pH was calculated from added amount of HCl. 
The titration and UV-VIS data were treated simultaneously with OPIUM program package.53, 54 
Calculated constants are concentration constants defined as βhl = [HhLl] / [H]h·[L]l or βhlm = 
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[HhLlMm] / [H]h·[L]l·[M]m and standard deviations are given directly by the program. pM values 
were also calculated by OPIUM from determined protonation and stability constants. 
The full version of the OPIUM program is available (free of charge) on 
http://www.natur.cuni.cz/_kyvala/opium.html 
Radiolabelling 
The IGG100 generator was eluted with 0.6 M aq. HCl (3 mL). This eluate (300-200 MBq) was 
diluted with H2O (15 mL) and passed through a Strata-X-C 33 μM Cation Mixed-mode polymeric 
support. The activity was liberated from the column using 98:2 acetone:0.1 M aq. HCl (1 mL). 
Aliquots (~30 MBq) of this solution were dried under a stream of inert gas at 90 oC and allowed 
to cool before use. 1 mL of ligand solution was added to the dried 68Ga and shaken. 5 μL aliquots 
were taken for analysis by TLC and 20 μL aliquots for analysis by HPLC. 
TLC analysis was performed on Kieselgel 60 F254 plates (Merck) with an eluate of 0.1 M citric 
acid in water. HPLC analysis was carried out using an Agilent Zorbax Eclipse XDB-C18 column 
and a solvent system of water + 0.1% TFA and methanol. 
Assessment of stability to apo-transferrin 
100 μL of radiolabelling solution containing 100 μM H3Dpaa in 0.1 M acetate buffer (pH 4.5) after 
incubation with gallium-68 for 5 minutes was added to 600 μL of 1 mgml-1 transferrin in 0.1 M 
sodium hydrogen carbonate solution to give a final pH of 7.2. This solution was incubated at 37 
oC with aliquots taken at 60 and 120 minutes for HPLC analysis (figure S13). 
Assessment of stability in foetal bovine serum 
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100 μL of radiolabelling solution containing 100 μM ligand in PBS (pH 7.4) was added to 1.5 mL 
of foetal bovine serum and incubated at 37 oC. Aliquots were taken at 30minutes for TLC analysis 
(figure S14). 
Analytical HPLC gradient: Solvent A: Water + 0.1% TFA, Solvent B: Methanol. Flow rate = 1 
mL min-1. Column Size: 4.6 x 150 mm with 4.6 x 12.5 mm guard column [Time / mins](A:B). [0-
3](95:5). [3-18](95:5 – 5:95). [18-20](5:95). [20-25](5:95 – 95:5). [25-30](95:5) 
Semi-preparative HPLC gradient: Solvent A: Water + 0.1% TFA, Solvent B: Methanol. Flow rate 
= 3 mL min-1. Column Size: 9.4 x 250 mm. [Time / mins](A:B). [0-10](95:5). [10-11](95:5 – 5:95). 
[11-14](5:95). [14-15](5:95-95:5) [15-20](95:5) 
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Scheme 1. Synthetic scheme for the synthesis of ligands reported in this paper. i) K2CO3, KI, 
MeCN, 60 oC, 12 h. ii) 6 M HCl, reflux, 16 h, iii) GaCl3, H2O, pH 4 
 
A B  
Figure 2. ORTEP representations of molecular structures of A) [Ga(H2O)(Dpaa)]‡ and B) 
[Ga(H2O)(Dpaa.ga)]§ obtained by single crystal x-ray crystallography (drawn with 30% certainty, 
solvent molecules omitted for clarity). 
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Table 1. Selected crystallographic 
parameters (Bond lengths) for GaDpaa 
and GaDpaa.ga 
 Bond length / Å 
Bond GaDpaa GaDpaa.ga 
O1-Ga1 2.0441(10) 2.001(6) 
N1-Ga1 2.2354(11) 2.191(7) 
N2···Ga1 2.4880(11) 2.513(8) 
N3-Ga1 2.2017(12) 2.180(7) 
O5-Ga1 2.0229(10) 2.034(6) 
O3-Ga1 1.9173(10) 1.942(6) 
O1W-Ga1 1.9109(10) 1.952(5) 
 
Table 2. Selected crystallographic parameters 
(Bond angles) for GaDpaa and GaDpaa.ga 
 Bond Angle / o 
Angle GaDpaa GaDpaa.ga 
O1-Ga1-N1 73.97(4) 76.1(3) 
N1-Ga1-N3 135.16(4) 133.7(3) 
N3-Ga1-O5 74.95(4) 75.2(3) 
O5-Ga1-O1 75.92(4) 75.5(3) 
O3-Ga1-O1 90.08(4) 93.8(3) 
O3-Ga1-N1 88.09(4) 86.0(2) 
O3-Ga1-N3 91.36(4) 96.4(3) 
O3-Ga1-O5 92.23(4) 90.7(2) 
O3-Ga1-O1W 175.40(4) 172.8(2) 
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Figure 3. Speciation diagrams for Ga(III) – ligand systems. A) H3Dpaa, B) H3Dpaa.dab(NH2), C) 
H4Dpaa.ga (T = 25 ºC, I = 0.1 M (NMe4)Cl, [L] = [Ga(III)] =0.004 M). 
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Table 3. Stepwise protonation constants obtained for 
ligands by potentiometrya 
 H3Dpaa H3Dpaa.dab H4Dpaa.ga 
logK1 7.38 11.35 7.17 
logK2 3.73 5.39 4.67 
logK3 2.82 3.77 3.92 
logK4 - 2.69 2.75 
[a] ([L] = 0.004 M, T = 25 oC, I = 0.1 M (NMe4)Cl) 
 
Table 4. Stability constants (logK) obtained for 
complexes. 
Metal Ion H3Dpaa H3Dpaa.dab H4Dpaa.ga 
Ga(III) 18.53[a] 22.08[b] 
16.13[b,c] 
18.36[b] 
Cu(II) 10.85[b] 19.1[b,d] 14.52[b,d] 
Zn(II) 11.93[b] 15.8[b,d] 13.38[b,d] 
[a] Determined by UV-VIS titration [L] = [M] = 0.1 
mM, T = 25 oC, pH = 2-7 [b]Determined by 
potentiometric titration ([L] = [M] = 0.004 M, T = 25 
oC, I = 0.1 M (NMe4)Cl), [c]Constant (logKGaHL) 
describing equilibrium Ga(III) + (HL)2– ↔ 
[Ga(HL)]+ where the amine group deprotonation and 
hydroxido species formation are not considered. [d] 
Determined by UV-VIS titration ([L] = [M] = 0.01 
mM, T = 25 oC, pH = 0-2) 
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Figure 4. pH titration of radiochemical yield for formation of [68Ga][Ga(Dpaa)]. Circles, I = 
unbuffered aqueous solution. Squares, I = 0.1 M buffered solution, ([H3Dpaa] = 100 μM, T = 25 
oC, t = 15 minutes) 
 
Figure 5. Radiochemical yield for formation of [68Ga][Ga(Dpaa)] at varying concentrations. 
Circles = pH 4.0, I = 0.1 M acetate solution. Triangles = pH 7.4, I = 0.1 M phosphate solution, (T 
= 25 oC, t = 15 minutes) 
 
Table 5. Radiochemical yields of labelling reactions[a] 
Ligand H3Dpaa H3Dpaa.dab H4Dpaa.ga 
pH 4.0[b] 99% 99% 99% 
pH 7.4[c] 95% 84% 94% 
[a] [L] = 100 μM ligand, t = 5 minutes [b] I = 0.1 M Acetate, 
T = 25 oC, [c] I = PBS, T = 37.7 oC 
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Notes 
††H4Dpaa.ga crystal structure data: refined formula C19H19N3O8; Mr  = 417.37; crystal dimensions 
0.275 × 0.130 × 0.056 mm3; Monoclinic; P21/n; a = 7.0852(6) Å, b = 32.290(4) Å, c = 7.6786(6) 
Å, β = 94.108(7)°, V = 1752.2(3) Å3; Z = 4; ρcalcd = 1.582 g cm−3; μ = 0.125 mm−1; Mo Kα radiation 
λ = 0.7173 Å; T = 150 K; 2θmax = 51.10 º; no. of reflections measured (independent) = 9845 (3229); 
Rint = 0.0571; R = 0.0401; wR2 = 0.0612; ρmax/min = 0.172 / −0.197  e Å−3; data collected using 
a Stoe IPDS2 diffractometer; structure solved by routine dual space methods and refined against 
all observed F2 values.  
‡GaDpaa crystal structure data: refined formula C16H20Ga1N3O10; Mr = 484.07; crystal dimensions 
0.040 × 0.005 × 0.005 mm3; Triclinic; P-1; a = 7.06810(10) Å, b = 8.21920(10) Å, c = 15.9952(2) 
Å,α = 93.6180(10)°, β = 93.7920(10)°, γ = 91.9130(10)°, V = 924.69(2) Å3; Z = 1; ρcalcd = 1.739 
g cm−3; μ = 1.425 mm−1; synchrotron radiation λ = 0.6889 Å; T = 100 K; 2θmax = 72.358 º; no. of 
reflections measured (independent) = 20701 (8614); Rint = 0.057; R = 0.0425; wR2 = 0.1062; 
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ρmax/min = 1.606 / −0.543  e Å−3; data collected at Diamond synchrotron UK, station I19; structure 
solved by routine dual space methods and refined against all observed F2 values.  
§GaDpaa.ga crystal structure data: refined formula C19H24GaN3O12.5; Mr = 564.12; crystal 
dimensions 0.060 × 0.005 × 0.005 mm3; Orthorhombic; Pccn; a = 20.7850(12) Å, b = 30.2224(18) 
Å, c = 7.2085(6) Å, V = 4528.2(5) Å3; Z = 8; ρcalcd = 1.646 g cm−3; μ = 1.186 mm−1; synchrotron 
radiation λ = 0.6889 Å; T = 100 K; 2θmax = 49.67 º; no. of reflections measured (independent) = 
12211 (4251); Rint = 0.2109; R = 0.0999; wR = 0.2359; ρmax/min = 2.429 / −1.265 e Å−3; 
disordered water was modelled using the SQUEEZE routine; data collected at Diamond 
synchrotron UK, station I19; the crystal suffers from radiation damage but structure solution and 
refinement were routine; structure solved by routine dual space methods and refined against all 
observed F2 values.  
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